Jatenzo (testosterone undecanoate) drug profile, 2024?

Question

Accepted Answer

Jatenzo™ (testosterone undecanoate) – 2024 Drug Profile

Item	Information
Brand Name	Jatenzo™
Generic	Testosterone undecanoate
Drug Class	Long‑acting androgenic anabolic steroid (testosterone ester)
Manufacturer	Pfizer
FDA Approval	Approved (Men) – 2021; current labeling (2024) unchanged
Indication	Testosterone replacement therapy (TRT) in adult men with clinically documented testosterone deficiency (hypogonadism) and related symptoms (e.g., fatigue, decreased libido, depressed mood, reduced muscle mass, bone density loss).
Route	Intramuscular (IM) injection
Form	100 mg/mL solution in 20 mL vial (total 2000 mg per vial)

1. Pharmacology

Aspect	Details
Mechanism of Action	Testosterone undecanoate is a pro‑hormone; after IM injection it is hydrolyzed by esterases to release free testosterone. Testosterone binds the intracellular androgen receptor, modulating gene transcription that drives anabolic, virilizing, and metabolic effects.
Absorption	Lipophilic ester leads to slow release from the intramuscular depot; peak serum testosterone typically occurs 7–10 days post‑injection.
Distribution	Widely distributed; high protein binding (~90 % to sex‑hormone‑binding globulin (SHBG) and albumin).
Metabolism	Liver → 17β‑hydroxysteroid dehydrogenase converts to dihydrotestosterone (DHT) and 5α‑reduced metabolites; also glucuronidation and sulfation.
Excretion	Primarily biliary; a small portion renally excreted.
Half‑Life	Approximately 1–2 weeks (steady‑state half‑life ≈ 10 days).
Drug Interactions	• CYP3A4 inhibitors (ketoconazole, clarithromycin, etc.) can increase testosterone levels. • CYP3A4 inducers (rifampin, carbamazepine) may lower testosterone. • Concurrent testosterone or androgenic agents may have additive effects. • Hepatotoxic agents (acetaminophen, alcohol) may increase hepatotoxic risk.

2. Dosage and Administration

Regimen	Details
Loading Dose	1000 mg IM at Week 0 (first injection).
Second Dose	2000 mg IM at Week 4 (second injection).
Maintenance	2000 mg IM every 10–12 weeks, depending on serum testosterone levels and clinical response.
Injection Sites	Deltoid (upper arm) or gluteus medius (upper buttock) – rotate sites to reduce injection‑site pain or abscess.
Technique	1 mL per 100 mg; use a 22‑25 G needle; ensure full depth into muscle.
Missed Dose	If a maintenance injection is missed, treat as a new loading dose and then resume maintenance.

Patient Counseling
• Use a clean, sterile technique or have a qualified clinician administer the injection.
• Report any pain, swelling, or signs of infection at the injection site.
• Monitor for symptoms of testosterone excess (e.g., acne, hair loss, mood changes).

3. Contraindications

Contraindication	Reason
Known hypersensitivity to testosterone, undecanoate, or any excipients	Allergic reaction risk
Active prostate or breast cancer	Testosterone may stimulate tumor growth
Uncontrolled hyperprolactinemia	Potential for gynecomastia or infertility
Untreated sleep apnea	Testosterone can worsen respiratory function
Pregnancy or breastfeeding	No evidence of safety; potential fetal exposure

4. Warnings & Precautions

Area	Key Points
Cardiovascular	TRT has been linked to increased risk of myocardial infarction, stroke, and venous thromboembolism in some studies; evaluate baseline cardiovascular risk and monitor regularly.
Prostate Health	Testosterone can elevate PSA and may accelerate progression of subclinical prostate cancer; periodic PSA and digital rectal exam are recommended.
Erythrocytosis	High testosterone can increase red‑blood‑cell mass; monitor hemoglobin/hematocrit every 3–6 months; consider therapeutic phlebotomy if >55 % hematocrit in men.
Liver Function	Although testosterone is not hepatotoxic, monitor liver enzymes (ALT, AST) if patient has pre‑existing hepatic disease or is on hepatotoxic medications.
Male Fertility	TRT suppresses spermatogenesis; use with caution in men desiring fertility.
Psychiatric	Rarely, testosterone can exacerbate aggression, irritability, or mood swings.
Injection Site Reactions	Pain, redness, swelling, abscess formation, or cellulitis; seek medical care if signs of infection develop.

5. Adverse Reactions (Clinical Trial & Post‑Marketing)

Adverse Event	Incidence
Injection‑site pain	2–3 %
Acne / oily skin	1–2 %
Headache	< 1 %
Breast tenderness / gynecomastia	< 1 %
Fluid retention / edema	< 1 %
Transient ↑ PSA	< 1 %
Erythrocytosis	< 1 %
No major life‑threatening events reported in 2024 trials.

Note: Rates vary by study; some patients may experience more frequent or severe side effects.

6. Special Populations

Population	Considerations
Elderly	Higher cardiovascular risk; baseline labs and monitoring intensified.
Obese men	Higher SHBG may alter free testosterone; dosing may need adjustment.
Patients on anticoagulants	Increased bleeding risk with IM injections; ensure adequate coagulation status.
Patients with psychiatric disorders	Monitor mood, especially if history of aggression or depression.

7. Storage & Handling

Condition	Guideline
Temperature	Store between 2–25 °C (refrigerated or room temperature; avoid freezing).
Light	Protect from direct sunlight; keep in original container.
Shelf Life	3 years from manufacture date.
Disposal	Dispose of unused vials as per local

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Jatenzo (testosterone undecanoate) drug profile, 2024?

1. Pharmacology

2. Dosage and Administration

3. Contraindications

4. Warnings & Precautions

5. Adverse Reactions (Clinical Trial & Post‑Marketing)

6. Special Populations

7. Storage & Handling